Stock Market Reviews

Read and share opinions on VTVT (vTv Therapeutics Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• All You Need to Know About vTv Therapeutics (VTVT) Rating Upgrade to Buy
  Nov 11, 2025
• VTv Therapeutics: Q3 Earnings Snapshot
  Nov 6, 2025
• vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
  Nov 6, 2025
• vTv Therapeutics Announces New Appointments to its Scientific Advisory Board
  Oct 9, 2025
• vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting
  Sep 15, 2025
• UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences
  Sep 3, 2025
• vTv Therapeutics to Participate in Upcoming September Investor Conferences
  Sep 3, 2025
• vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund
  Sep 2, 2025
• VTv Therapeutics: Q2 Earnings Snapshot
  Aug 12, 2025
• vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
  Aug 12, 2025
• vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin
  Aug 11, 2025
• vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes
  Aug 7, 2025
• vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series
  Jun 11, 2025
• vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin
  May 19, 2025
• VTv Therapeutics: Q1 Earnings Snapshot
  May 15, 2025
• vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update
  May 15, 2025
• vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes
  May 15, 2025
• vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
  Mar 20, 2025